These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 25993185)

  • 1. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
    Dorff TB; Gross ME
    Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
    Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
    J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeted radionuclide therapy for castration-resistant prostate cancer].
    Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
    Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
    Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
    Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
    Iizuka J
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():16-23. PubMed ID: 30489033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
    Miranda J; Viñal D; Pinto Á
    Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radium-223 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) : The androgen receptor-independent active agent in the therapeutic sequence].
    König F; Strauß A; Johannsen M; Mommsen C; Fricke E; Klier J; Mehl S; Pfister D; Sahlmann CO; Werner A; Goebell PJ
    Urologe A; 2020 Jan; 59(1):53-64. PubMed ID: 31598745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer.
    Buroni FE; Persico MG; Pasi F; Lodola L; Nano R; Aprile C
    Anticancer Res; 2016 Nov; 36(11):5719-5730. PubMed ID: 27793893
    [No Abstract]   [Full Text] [Related]  

  • 11. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 12. [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
    Mortensen J; Højgaard L
    Ugeskr Laeger; 2014 Jul; 176(30):1399-402. PubMed ID: 25292232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection.
    Den RB; George D; Pieczonka C; McNamara M
    Am J Clin Oncol; 2019 Apr; 42(4):399-406. PubMed ID: 30844849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
    Winter BM; von Rundstedt FC; Grimm MO
    Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radium-223 in metastatic castration resistant prostate cancer.
    Vuong W; Sartor O; Pal SK
    Asian J Androl; 2014; 16(3):348-53. PubMed ID: 24713838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
    Küronya Z; Sinkovics I; Ágoston P; Bíró K; Bodrogi I; Böde I; Dank M; Gyergyay F; Vajdics T; Kolonics Z; Nagyiványi K; Rúzsa Á; Géczi L
    Pathol Oncol Res; 2017 Oct; 23(4):777-783. PubMed ID: 28074331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
    Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
    Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary.
    O'Sullivan JM; Abramowitz E; Sierra-Scacalossi L
    Future Oncol; 2023 May; 19(15):1021-1028. PubMed ID: 36942803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of mCRPC patients treated with
    Frantellizzi V; De Vincentis G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(6):391-392. PubMed ID: 32426304
    [No Abstract]   [Full Text] [Related]  

  • 20. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
    Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
    Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.